These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1232 related articles for article (PubMed ID: 21044553)

  • 21. Positron emission tomography (PET) and magnetic resonance imaging (MRI) for assessing tumour resectability in advanced epithelial ovarian/fallopian tube/primary peritoneal cancer.
    Roze JF; Hoogendam JP; van de Wetering FT; Spijker R; Verleye L; Vlayen J; Veldhuis WB; Scholten RJ; Zweemer RP
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012567. PubMed ID: 30298516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
    Xiao Y; Wang L; Jiang X; She W; He L; Hu G
    Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PET/CT and MRI for Identifying Axillary Lymph Node Metastases in Breast Cancer Patients: Systematic Review and Meta-Analysis.
    Zhang X; Liu Y; Luo H; Zhang J
    J Magn Reson Imaging; 2020 Dec; 52(6):1840-1851. PubMed ID: 32567090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A two-way comparison of whole-body 18FDG PET-CT and whole-body contrast-enhanced MRI for distant metastasis staging in patients with malignant tumors: a meta-analysis of 13 prospective studies.
    Li J; Zhou H; Zhang X; Song F; Pang X; Wei Z
    Ann Palliat Med; 2020 Mar; 9(2):247-255. PubMed ID: 32233618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies.
    Taylor SA; Mallett S; Miles A; Morris S; Quinn L; Clarke CS; Beare S; Bridgewater J; Goh V; Janes S; Koh DM; Morton A; Navani N; Oliver A; Padhani A; Punwani S; Rockall A; Halligan S
    Health Technol Assess; 2019 Dec; 23(66):1-270. PubMed ID: 31855148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
    Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer.
    Ghaneh P; Hanson R; Titman A; Lancaster G; Plumpton C; Lloyd-Williams H; Yeo ST; Edwards RT; Johnson C; Abu Hilal M; Higginson AP; Armstrong T; Smith A; Scarsbrook A; McKay C; Carter R; Sutcliffe RP; Bramhall S; Kocher HM; Cunningham D; Pereira SP; Davidson B; Chang D; Khan S; Zealley I; Sarker D; Al Sarireh B; Charnley R; Lobo D; Nicolson M; Halloran C; Raraty M; Sutton R; Vinjamuri S; Evans J; Campbell F; Deeks J; Sanghera B; Wong WL; Neoptolemos JP
    Health Technol Assess; 2018 Feb; 22(7):1-114. PubMed ID: 29402376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.
    Daamen LA; Groot VP; Goense L; Wessels FJ; Borel Rinkes IH; Intven MPW; van Santvoort HC; Molenaar IQ
    Eur J Radiol; 2018 Sep; 106():128-136. PubMed ID: 30150034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis.
    Wei J; Pei S; Zhu X
    Oral Oncol; 2016 Jan; 52():11-7. PubMed ID: 26547126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
    Facey K; Bradbury I; Laking G; Payne E
    Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis.
    Choi SH; Kim SY; Park SH; Kim KW; Lee JY; Lee SS; Lee MG
    J Magn Reson Imaging; 2018 May; 47(5):1237-1250. PubMed ID: 28901685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.
    Goense L; van Rossum PS; Reitsma JB; Lam MG; Meijer GJ; van Vulpen M; Ruurda JP; van Hillegersberg R
    J Nucl Med; 2015 Jul; 56(7):995-1002. PubMed ID: 25952733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis.
    He YQ; Gong HL; Deng YF; Li WM
    Acta Radiol; 2014 Apr; 55(3):309-17. PubMed ID: 24081215
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head-to-Head Comparison of the Diagnostic Performance of FDG PET/CT and FDG PET/MRI in Patients With Cancer: A Systematic Review and Meta-Analysis.
    Singnurkar A; Poon R; Metser U
    AJR Am J Roentgenol; 2024 Sep; 223(3):e2431519. PubMed ID: 39016450
    [No Abstract]   [Full Text] [Related]  

  • 40. Positron emission tomography/computed tomography outperforms MRI in the diagnosis of local recurrence and residue of nasopharyngeal carcinoma: An update evidence from 44 studies.
    Li Z; Li Y; Li N; Shen L
    Cancer Med; 2019 Jan; 8(1):67-79. PubMed ID: 30578604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.